All Stories

LifeMine Therapeutics lays off staff, reprioritizes to drill lead asset into clinic

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical development of its lead asset, LifeMine CEO Gregory Verdine, Ph.D., confirmed to Fierce Biotech.

Mar 31, 2025 - 22:46
 0
LifeMine Therapeutics lays off staff, reprioritizes to drill lead asset into clinic
Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical development of its lead asset, LifeMine CEO Gregory Verdine, Ph.D., confirmed to Fierce Biotech.
Read More

Tags:

Previous Article

The AI revolution comes to protein sequencing

Next Article

Trump to Unveil Country-Based Tariffs Apr. 2 in Rose Garden

Related Posts

Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine's Crenessity

Harbour offshoot pens $395M biobucks deal for preclinic...

Feb 26, 2025  0

With $200M in seed funding, Flagship-backed Lila Sciences touts ambitious AI vision

With $200M in seed funding, Flagship-backed Lila Scienc...

Mar 10, 2025  0

'Tough but necessary decisions': Frontier Medicines lays off staff to streamline operations

'Tough but necessary decisions': Frontier Medicines lay...

Feb 9, 2025  0